Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
NORINYL 1+35 21-DAY is an oral contraceptive tablet containing norethindrone and ethinyl estradiol, approved in 1974. It prevents pregnancy through hormonal suppression of ovulation and is taken daily for 21 days followed by a 7-day pill-free interval. This is a legacy combination oral contraceptive (COC) product in the mature contraception market.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely in consolidation or support mode, with limited commercial expansion opportunity.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NORINYL 1+35 offers limited upside given the product's LOE trajectory and minimal clinical innovation pipeline. Career value is primarily in legacy product management, compliance, and risk mitigation rather than market growth or cutting-edge pharmaceutical development.
Worked on NORINYL 1+35 21-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.